REFRACTORY ACUTE LEUKEMIA
Clinical trials for REFRACTORY ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids whose leukemia Won't quit
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination (Hyper-CVAD and venetoclax) for children and young adults (ages 2-21) whose leukemia has returned or hasn't responded to other treatments. The main goal is to see how much of the drug combination…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New Two-Drug attack on aggressive leukemias that resist standard care
Disease control Recruiting nowThis early-stage study is testing whether combining two oral drugs, revumenib and mezigdomide, is safe and effective for people with specific types of acute leukemia that have returned or not responded to prior treatments. The trial will enroll about 52 participants aged 12 and o…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for kids with tough leukemia: trial tests powerful drug trio
Disease control Recruiting nowThis study aims to find the safest and most effective dose of a new drug, ziftomenib, when given with two other drugs (venetoclax and azacitidine) to children and young adults whose acute leukemia has come back or hasn't responded to other treatments. It will enroll about 22 part…
Matched conditions: REFRACTORY ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC